NeOnc Technologies Holdings, Inc. reported an overstatement of share-based compensation expense related to approximately 1.49 million restricted stock units issued on January 4, 2024, leading to the restatement of its financials for the quarter ending March 31, 2025, which is detailed in their upcoming report for the quarter ending June 30, 2025.